Carvedilol significantly reduced mortality from cardiovascular causes and Study Rundown: The CAPRICORN trial demonstrated that. London, UK – Results of the CAPRICORN trial confirm the benefit of the beta blocker carvedilol (Coreg® – GlaxoSmithKline) in reducing. Description: The CArvedilol Post-infaRct survIval COntRolled evaluatioN ( CAPRICORN) trial was a randomized, placebo-controlled trial.
|Published (Last):||5 April 2013|
|PDF File Size:||11.27 Mb|
|ePub File Size:||3.71 Mb|
|Price:||Free* [*Free Regsitration Required]|
Editor in chief Boytsov S. N Engl J Med ; Generally, the patients recruited to these trials were at low risk: The primary endpoint was all-cause mortality or hospital admission for cardiovascular problems. Cardiovascular mortality, non-fatal myocardial infarctions, and all-cause mortality or non-fatal myocardial infarction were also lower on carvedilol than on placebo.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: Analysis was by intention to treat. Acta Med Scand ; 3: We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice.
Metoprolol in acute myocardial infarction. JAMA ; Clin Res Cardiol ;95 1: Center for Drug Evaluation and Research, U. Early intravenous then oral metoprolol in 45 patients with acute myocardial infarction: Am J Med ; 7: Lopressor Intervention Trial Research Group.
Pharma commercial intelligence, news & analysis | Evaluate
Carvedilol protects better against vascular events than metoprolol in heart failure: Randomised trial of intravenous atenolol among 16 cases of suspected acute myocardial infarction: J Am Coll Cardiol ;51 2: Possible indications and treatment schemes for carvedilol in patients with acute MI are discussed. Article Tools How to cite item. Clopidogrel and metoprolol in myocardial infarction. A double-blind randomized trial.
Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. S Food and Drug Administration. Am Heart J ; 4: Email this article Login required. J Am Coll Cardiol ;49 9: Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Last changes in guidelines regarding beta-blockers prescription to patients with MI are presented. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction.
Effect on mortality of metoprolol in acute myocardial infarction. This work is licensed under a Creative Commons Attribution 4. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention — the PASSAT Study.
Clin Res Cardiol ;95 2: Int J Cardiol ;10 3: A placebo-controlled, randomized trial. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: Effect of timing, dosage, and infarct location.
These beneficial effects are additional to those of evidence-based treatments for acute myocardial infarction including ACE inhibitors. Email the author Login required. Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients cqrvedilol atrial fibrillation: MoscowRussia Petroverigsky per. Keywords acute coronary syndrome ambulatory blood pressure monitoring amlodipine apixaban arterial hypertension atherosclerosis atrial fibrillation beta-blockers cardiovascular diseases chronic heart failure hypertension ischemic heart disease lisinopril metabolic syndrome myocardial infarction obesity risk factors rivaroxaban statins stroke warfarin.
Eur Heart J ;8 Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for capircorn infarction: Am J Med ; 5: Keywords myocardial infarction, beta-blocker, carvedilol, metoprolol.
METOPROLOL AND CARVEDILOL IN THERAPY OF ACUTE MYOCARDIAL INFARCTION: WHEN AND WHICH DRUG TO PREFER
In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions.
The beneficial effects of beta-blockers on long-term outcome after acute myocardial infarction were shown before the introduction of thrombolysis and angiotensin-converting-enzyme ACE inhibitors. Study medication was progressively increased to a maximum of 25 mg twice daily during the next weeks, and patients were followed up until the requisite number of primary endpoints had occurred. Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction.
Eur Heart J ;29